Sep 2026· Journal of Biological Chemistry· pp.
113590
· 0 citations· 86 references
Medicine
TL;DR
It is demonstrated that loss of EAG1 markedly suppresses tumor growth and metastasis of A549 NSCLC cells using a combination of tissue culture, xenograft and multi-omics approaches, highlighting EAG1 as a potential therapeutic target in NSCLC.
Abstract
The voltage-gated potassium channel EAG1 is aberrantly expressed in many cancers, yet its mechanistic contributions to tumor growth and metastasis in non-small cell lung cancer (NSCLC) remains poorly defined. Here, we establish a genetic EAG1 knockout in A549 NSCLC cells and demonstrate that loss of EAG1 markedly suppresses tumor growth and metastasis using a combination of tissue culture, xenograft and multi-omics approaches. EAG1 knockout reduced proliferative ability across multiple in vitro assays and in vivo zebrafish xenografts. Furthermore, loss of EAG1 induced G1-phase cell-cycle arrest, accompanied by broad suppression of cell-cycle regulators. Additionally, knocking out EAG1 significantly reduced migratory and invasive properties in vitro, and markedly impaired extravasation in vivo. Integrated transcriptomic and proteomic analyses revealed that EAG1 regulates E2F signaling and epithelial-mesenchymal transition (EMT). Consistent with this, EAG1 knockout attenuated TGF-β-induced EMT by disrupting the cadherin switch, a key mechanism for EMT, and abolished EMT-driven migration, demonstrating that EAG1 is required for the acquisition of a migratory phenotype. Together, these findings establish EAG1 as a central regulator of proliferation and metastasis of A549 cells, highlighting EAG1 as a potential therapeutic target in NSCLC.
It is demonstrated that EZH2 promotes NSCLC progression through activation of the JAK2/STAT3 signaling pathway, identifying the EZH2-JAK2/STAT3 axis as a potential therapeutic vulnerability in this malignancy.
The findings suggest that the effects of MIR100HG on oncogenic signaling are highly dependent on the cellular oxygenation context and that hypoxia reshapes the downstream signaling consequences of MIR100HG expression in HCC cells.
E. Tokay, Sevin Avsar Koc, Aylin Turkoglu Dulger et al.· Functional & Integrative Gen...· 0 citations
Pharmacologic suppression of IL20RB by APAP presents a novel therapeutic strategy, positioning IL20RB as a promising prognostic biomarker and therapeutic target in NSCLC.
Yang-Hao Wang, Guo-Yun Li, Wei-Zhou Wang et al.· Lung Cancer· 0 citations
Gefitinib resistance remains a major obstacle to the effective treatment of non-small cell lung cancer (NSCLC), and the underlying molecular mechanisms have not yet been fully elucidated. Lysosomal-associated transmembrane protein 4B (LAPTM4B) has been shown to be involved in cancer progression, but its specific role i...
Yu Jiang, Wen-Jing Xie, Rong-Wei Chen et al.· Biochimica et biophysica act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.